Fund manager

Baker Brothers Investments

Baker Brothers Investments · Biotech

Quarter ending 30 Jun 2026 · Filed 14 Aug 2026 · 83 positions · $19.9B reported

Investor focused on biotechnology and life sciences. Added from a public list of the largest hedge fund managers.

Top holdings

Top 15 of 83 positions by reported value. Weight is each position's share of the 13F total. Source: SEC Form 13F-HR, quarter ending 30 Jun 2026, filed 14 Aug 2026.
CompanyWeightValue (13F)
Incyte Corporation (INCY)17.5%$3.5B
Beone Medicines Ltd. (ONC)12.6%$2.5B
Revolution Medicines, Inc. (RVMD)10.8%$2.1B
Madrigal Pharmaceuticals, Inc. (MDGL)5.8%$1.2B
Acadia Pharmaceuticals Inc. (ACAD)5.5%$1.1B
Kymera Therapeutics, Inc. (KYMR)5.0%$992.7M
Insmed Incorporated (INSM)4.7%$937.8M
Celcuity Inc. (CELC)4.2%$828.2M
Kodiak Sciences Inc. (KOD)3.9%$776.1M
Rhythm Pharmaceuticals, Inc. (RYTM)3.1%$622.3M
Praxis Precision Medicines, Inc. (PRAX)3.0%$587.0M
Alkermes Plc2.6%$524.6M
Summit Therapeutics Inc. (SMMT)2.4%$477.7M
Grail, Inc. (GRAL)1.4%$275.0M
Abcellera Biologics Inc. (ABCL)1.3%$259.1M

Source: Form 13F-HR filing on SEC EDGAR (accession 0001104659-26-097191), for the quarter ending 30 Jun 2026, filed 14 Aug 2026. A 13F lists long US-listed equity positions only, filed up to 45 days after quarter end, so it is a look back, not a live portfolio. Values are as reported in the filing.

Open the interactive profile: buys and sells, track record, mimic portfolio